clofibric acid and fenofibrate

clofibric acid has been researched along with fenofibrate in 82 studies

Research

Studies (82)

Timeframe	Studies, this research(%)	All Research%
pre-1990	13 (15.85)	18.7374
1990's	31 (37.80)	18.2507
2000's	32 (39.02)	29.6817
2010's	6 (7.32)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beneton, V; Boullay, AB; Boyer, T; Brewster, AG; Donche, F; Forest, MC; Fouchet, MH; Gellibert, FJ; Grillot, DA; Lambert, MH; Laroze, A; Le Grumelec, C; Linget, JM; Montana, VG; Nguyen, VL; Nicodème, E; Patel, V; Penfornis, A; Pianetti, PM; Pineau, O; Pohin, D; Potvain, F; Poulain, G; Ruault, CB; Saunders, M; Sierra, ML; Toum, J; Xu, HE; Xu, RX	1
Headey, SJ; Hughes, ML; Laguerre, A; Mohanty, B; Patil, R; Porter, CJ; Scanlon, MJ; Wielens, J; Williams, ML	1
Aarsland, A; Berge, RK	1
Galteau, MM; Guéguen, R; Leroy, P; Liu, HF; Magdalou, J; Nicolas, A; Siest, G; Vincent-Viry, M	1
Frishman, WH; Kahn, S; Zimetbaum, P	1
Kłosiewicz-Latoszek, L; Szostak, WB	1
Fournel, S; Magdalou, J; Pinon, P; Siest, G	1
Krause, BR; Newton, RS	1
Bonnefis, MT; Infante, R; Petit, D; Rey, C	1
Palmer, RH	1
Hunninghake, DB; Peters, JR	1
Beaumont, JL; Beaumont, V; Buxtorf, JC; Carcone, B; Doucet, F; Edouard, L; Jacotot, B	1
Bakir, R; Chanu, B; Djian, F; Goy-Loeper, J; Rouffy, J	1
Franceschini, G; Paoletti, R; Sirtori, CR	1
Santafé Oroz, J; Segarra Domènech, J	1
Canzler, H	1
Lehmann-Leo, W; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W; Wegscheider, K	1
Calder, D; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W	1
Schilling, A; Schwartzkopff, W	1
Bardot, O; Cherkaoui Malki, M; Clemencet, MC; Latruffe, N	1
Cornu-Chagnon, MC; Dupont, H; Edgar, A	1
Schonfeld, G	1
Cherkaoui Malki, M; el Kebbaj, MH; Latruffe, N	1
Dujovne, CA; Lozada, A	1
Devuyst, O; Goffin, E; Pirson, Y; van Ypersele de Strihou, C	2
Caldwell, J; Grubb, N; Weil, A	1
Bentejac, M; Bugaut, M; Causeret, C; Clemencet, MC	1
Shepherd, J	1
Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W	1
Accatino, L; Amigo, L; Andrade, L; Chianale, J; Gonzalez, S; Nervi, F; Pizarro, M; Rigotti, A; Vollrath, V; Wielandt, AM	1
Canepo-Anson, R; Collinson, PO; Hjelm, CJ	1
Walsh, KB; Wang, C	1
Desager, JP; Harvengt, C; Horsmans, Y; Vandenplas, C	1
Cuniberti, LA; Masnatta, LD; Rey, RH; Werba, JP	1
Murphy, MJ; O'Reilly, DS; Packard, CJ	1
Autier, P; Muls, E; Van Gaal, L; Vansant, G	1
Bournot, P; Bride, J; Duclos, S; Ramirez, LC	1
Deyashiki, Y; Hara, A; Ishikura, S; Katagiri, Y; Kato, M; Matsuura, K; Miyabe, Y; Sugiyama, T	1
Beaugrand, M; Bertrand, HJ; Castera, L; de Leusse, A; Ganne-Carrié, N; Guettier, C; Levecq, H; Plumet, Y; Trinchet, JC	1
Sinzinger, H	1
Kockx, M; Kooistra, T; Princen, HM	1
Derudas, B; Gervois, PP; Gonzalez, FJ; Kockx, M; Kooistra, T; Peters, JM; Poulain, P; Princen, HM; Staels, B	1
Wallace, KB; Zhou, S	1
Eriksson, P; Hamsten, A; Nilsson, L; Takemura, T	1
Desager, JP; Devuyst, O; Goffin, E; Jamar, F	1
Abramowicz, D; Antoine, M; Broeders, N; Knoop, C; Tielemans, C	1
Elisaf, M; Kakafika, A; Tsimihodimos, V	1
Bargman, JM; Lipscombe, J	1
Cwalina, L; Herman, ZS; Kalina, Z; Kowalski, J; Lebek, M; Okopien, B; Wisniewska-Wanat, M; Zielinski, M	1
Achimastos, A; Bairaktari, E; Elisaf, M; Goudevenos, J; Kakafika, A; Liamis, G; Miltiadous, G; Tsimihodimos, V	1
Athyros, V; Bairaktari, E; Elisaf, M; Ganotakis, E; Rizos, E; Seferiades, C; Tsimihodimos, V	1
Fujisaki, K; Itoh, Y; Maiguma, T; Makino, K; Oishi, R; Sasaguri, T; Takahashi-Yanaga, F; Teshima, D	1
Betz, W; Devroey, D; Duquet, W; Velkeniers, B	1
Dzúrik, R; Gajdos, M	1
Romaniv, S; Vecka, M; Zák, A; Zeman, M	1
Mikhailidis, DP; Wierzbicki, AS; Wray, R	1
Anderson, SP; Brown, AR; Brown, HR; Cariello, NF; Colton, HM; Dahl, RR; Hoivik, DJ; Kimbrough, CL; Miller, RT; Mirabile, RC; Morgan, RJ; Mudd, PN; Oliver, WB; Qualls, CW; Santostefano, MJ; Zhao, Z	1
Baldwin, GS; Ford, J; Lachal, S; Shulkes, A	1
Bozic, M; Fressart, MM; Keber, I; Sebestjen, M; Simcic, S; Stegnar, M; Zegura, B	1
Belowski, D; Herman, ZS; Huzarska, M; Kulach, A; Madej, A; Okopien, B; Stachura-Kulach, A; Zielinski, M	1
Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A	1
Davidson, MH	1
Buffat, L; Gijbels, MJ; Hofker, MH; Maeda, N; Noel, B; Shiri-Sverdlov, R; Staels, B; van Bilsen, M; van Gorp, PJ; Wouters, K	1
Duriez, P; Fruchart, JC	1
Rosenson, RS	1
Berneis, K; Rizzo, M	1
Duffner, JL; Jaipuri, FA; Koehler, AN; Krieger, M; Maliga, Z; Nieland, TJ; Shaw, JT	1
Bondarenko, EIu; Mel'nikova, NV; Zvenigorodskaia, LA	1
Benatar, JR; Stewart, RA	1
Cariou, B; Costet, P; Jarnoux, AL; Kourimate, S; Krempf, M; Langhi, C; Le May, C; Nguyen, P; Ouguerram, K; Zaïr, Y	1
Brinton, EA	1
Ansquer, JC; Aubonnet, P; Foucher, C; Le Malicot, K	1
Gaynor, P; Hsu, MH; Johnson, EF; Lasker, JM; Machemer, DEW; Savas, Ü; Tukey, RH	1
Jacobson, TA	1
Chalmers, DK; Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T; Wielens, J	1
Abourbih, S; Eisenberg, MJ; Filion, KB; Genest, J; Joseph, L; Pilote, L; Poirier, P; Rinfret, S; Schiffrin, EL	1
Kawashima, Y; Kudo, N; Mitsumoto, A; Okada, H; Sakamoto, T; Sunaga, K; Tsuda, T; Yamazaki, T	1
Ikeda, E; Kawashima, Y; Kudo, N; Mitsumoto, A; Sakamoto, T; Tanaka, S; Wakabayashi, M; Yamazaki, T	1
Hoshina, M; Karahashi, M; Kawashima, Y; Kudo, N; Mitsumoto, A; Sakamoto, T; Yamazaki, T	1
Fukuhara, H; Hoshina, M; Karahashi, M; Kawashima, Y; Kudo, N; Mitsumoto, A; Sakamoto, T; Yamazaki, T	1
Briel, M; Ferreira-González, I; Jakob, T; Nordmann, AJ; Schandelmaier, S	1

Reviews

18 review(s) available for clofibric acid and fenofibrate

Article	Year
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. Journal of clinical pharmacology, 1991, Volume: 31, Issue:1 Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Kidney Diseases; Lipoproteins, VLDL; Metabolic Clearance Rate; Triglycerides	1991
Effects of fibric acid derivatives on biliary lipid composition. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation	1987
Effect of fibric acid derivatives on blood lipid and lipoprotein levels. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Pentanoic Acids	1987
[Pharmacologic therapy of atherosclerosis (I). Current possibilities]. Medicina clinica, 1983, Nov-26, Volume: 81, Issue:17 Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Gemfibrozil; Glycosaminoglycans; Humans; Ion Exchange Resins; Lipoproteins; Nicotinic Acids; Pentanoic Acids; Probucol	1983
The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis, 1994, Volume: 111, Issue:2 Topics: Arteriosclerosis; Bezafibrate; Blood Coagulation; Clofibric Acid; Coronary Disease; Fenofibrate; Fibric Acids; Gemfibrozil; Hemostasis; Humans; Hypolipidemic Agents; Lipoproteins; Risk Factors	1994
Drug interactions with fibric acids. Pharmacology & therapeutics, 1994, Volume: 63, Issue:2 Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Drug Interactions; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipids	1994
Mechanism of action of fibrates. Postgraduate medical journal, 1993, Volume: 69 Suppl 1 Topics: Apolipoproteins B; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Receptors, LDL	1993
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis]. Deutsche medizinische Wochenschrift (1946), 1998, Sep-18, Volume: 123, Issue:38 Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis	1998
Drug treatment of combined hyperlipidemia. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2001, Volume: 1, Issue:5 Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Insulin Resistance; Liver Diseases; Obesity; Pancreatitis; Pregnancy; Pregnancy Complications	2001
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert opinion on drug safety, 2006, Volume: 5, Issue:1 Topics: Area Under Curve; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metabolic Syndrome; Risk Factors	2006
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs of today (Barcelona, Spain : 1998), 2006, Volume: 42, Issue:1 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, HDL; Clofibric Acid; Coronary Artery Disease; Fenofibrate; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Liver; PPAR alpha; Randomized Controlled Trials as Topic; Triglycerides	2006
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. Current medical research and opinion, 2007, Volume: 23, Issue:5 Topics: Bezafibrate; Clofibric Acid; Dyslipidemias; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Particle Size; Treatment Outcome	2007
Is it time to stop treating dyslipidaemia with fibrates? The New Zealand medical journal, 2007, Sep-07, Volume: 120, Issue:1261 Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic	2007
Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio? Current atherosclerosis reports, 2008, Volume: 10, Issue:1 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Diabetic Angiopathies; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Rhabdomyolysis; Risk Assessment; Triglycerides	2008
Fibrates and microvascular complications in diabetes--insight from the FIELD study. Current pharmaceutical design, 2009, Volume: 15, Issue:5 Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Fenofibrate; Humans; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Risk Factors	2009
Myopathy with statin-fibrate combination therapy: clinical considerations. Nature reviews. Endocrinology, 2009, Volume: 5, Issue:9 Topics: Clofibric Acid; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents	2009
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. The American journal of medicine, 2009, Volume: 122, Issue:10 Topics: Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome	2009
Fibrates for primary prevention of cardiovascular disease events. The Cochrane database of systematic reviews, 2016, 11-16, Volume: 11 Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Primary Prevention; Simvastatin; Stroke	2016

Trials

13 trial(s) available for clofibric acid and fenofibrate

Article	Year
Effects of fibric acid derivatives on biliary lipid composition. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation	1987
Effects of several lipid-lowering drugs on skin total and esterified cholesterol. Monographs on atherosclerosis, 1986, Volume: 14 Topics: Cholesterol Esters; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Probucol; Random Allocation; Skin	1986
Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B. Atherosclerosis, 1985, Volume: 54, Issue:3 Topics: Adult; Apolipoproteins A; Apolipoproteins B; Clofibrate; Clofibric Acid; Drug Evaluation; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Propionates; Time Factors	1985
Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels. The American journal of cardiology, 1983, Aug-22, Volume: 52, Issue:4 Topics: Adipose Tissue; Animals; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Bezafibrate; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipolysis; Lipoproteins, HDL; Niacin; Rats; Structure-Activity Relationship	1983
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV]. Die Medizinische Welt, 1982, Apr-30, Volume: 33, Issue:17 Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Propionates	1982
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Clinical cardiology, 1995, Volume: 18, Issue:11 Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides	1995
Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Atherosclerosis, 1996, Volume: 124 Suppl Topics: Adult; Chromatography, High Pressure Liquid; Clofibric Acid; Cross-Over Studies; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Fenofibrate; Fibric Acids; Half-Life; Humans; Hypolipidemic Agents; Lipase; Lipoprotein Lipase; Liver; Male; Nephelometry and Turbidimetry; Reference Values	1996
Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia. International journal of clinical pharmacology and therapeutics, 2001, Volume: 39, Issue:12 Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Fibrinogen; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Thrombosis; Tissue Plasminogen Activator; Treatment Outcome; Triglycerides	2001
Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia. Current medical research and opinion, 2002, Volume: 18, Issue:3 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Clofibric Acid; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenofibrate; Fibric Acids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Lipids; Liver; Male; Middle Aged; Pyrroles; Treatment Outcome	2002
[Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates]. Casopis lekaru ceskych, 2003, Volume: 142, Issue:8 Topics: Adult; Aged; Anticholesteremic Agents; Clofibric Acid; Drug Therapy, Combination; Female; Fenofibrate; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin	2003
Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thrombosis and haemostasis, 2004, Volume: 92, Issue:5 Topics: Adult; Arteriosclerosis; Blood Coagulation; Blood Coagulation Factors; Body Weight; C-Reactive Protein; Cholesterol, LDL; Clofibric Acid; Cytokines; Fenofibrate; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyridines; Risk Factors	2004
Field of confusion: future prospects for fibrate therapy in cardiovascular disease. Current atherosclerosis reports, 2006, Volume: 8, Issue:3 Topics: Aged; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents; Middle Aged; Placebos; Triglycerides	2006
[Pleiotropic effects of fibric acid derivatives (Lipanthyl-200) among patients with metabolic syndrome]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2007, Issue:1 Topics: Carbohydrate Metabolism; Clofibric Acid; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipid Metabolism; Lipids; Male; Metabolic Syndrome; Middle Aged	2007

Other Studies

52 other study(ies) available for clofibric acid and fenofibrate

Article	Year
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. Journal of medicinal chemistry, 2007, Feb-22, Volume: 50, Issue:4 Topics: Animals; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Crystallography, X-Ray; Dogs; Dyslipidemias; Humans; Ligands; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Molecular; PPAR alpha; Propionates; Protein Structure, Tertiary; Rats; Rats, Wistar; Structure-Activity Relationship; Thiazoles; Triglycerides	2007
Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein. ACS chemical biology, 2014, Nov-21, Volume: 9, Issue:11 Topics: Fatty Acid-Binding Proteins; Fluorescent Dyes; Humans; Nuclear Magnetic Resonance, Biomolecular; Protein Binding; Spectrometry, Fluorescence	2014
Peroxisome proliferating sulphur- and oxy-substituted fatty acid analogues are activated to acyl coenzyme A thioesters. Biochemical pharmacology, 1991, Jan-01, Volume: 41, Issue:1 Topics: Animals; Clofibric Acid; Enzyme Activation; Fatty Acids; Fenofibrate; Liver; Male; Microbodies; Oxides; Palmitoyl Coenzyme A; Palmitoyl-CoA Hydrolase; Rats; Rats, Inbred Strains; Sulfides; Sulfoxides	1991
Urinary glucuronide excretion of fenofibric and clofibric acid glucuronides in man. Is it polymorphic? European journal of clinical pharmacology, 1991, Volume: 41, Issue:2 Topics: Adult; Chromatography, High Pressure Liquid; Clofibric Acid; Female; Fenofibrate; Glucuronates; Humans; Hypolipidemic Agents; Male; Middle Aged; Molecular Structure; Polymorphism, Genetic; Reference Values	1991
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia. European journal of clinical pharmacology, 1991, Volume: 40, Issue:1 Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Probucol	1991
Differential induction profile of drug-metabolizing enzymes after treatment with hypolipidaemic agents. Xenobiotica; the fate of foreign compounds in biological systems, 1987, Volume: 17, Issue:4 Topics: Animals; Biphenyl Compounds; Body Weight; Butyrophenones; Clofibrate; Clofibric Acid; Cytochrome P-450 Enzyme System; Enzyme Induction; Epoxide Hydrolases; Fenofibrate; gamma-Glutamyltransferase; Glucuronosyltransferase; Hypolipidemic Agents; Lipids; Liver; Male; Rats; Rats, Inbred Strains; Structure-Activity Relationship	1987
Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats. Atherosclerosis, 1986, Volume: 59, Issue:1 Topics: Animals; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins E; Bezafibrate; Cholesterol, Dietary; Cholesterol, HDL; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Male; Pentanoic Acids; Rats; Rats, Inbred Strains; Valerates	1986
Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats. Atherosclerosis, 1988, Volume: 74, Issue:3 Topics: Animals; Apolipoproteins; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Hyperlipidemias; Lipids; Lipoproteins; Liver; Male; Propionates; Rats; Rats, Inbred Strains	1988
[Drug therapy of hypercholesterinemias (author's transl)]. MMW, Munchener medizinische Wochenschrift, 1980, Mar-28, Volume: 122, Issue:13 Topics: Adult; Bezafibrate; Cholestyramine Resin; Clofibric Acid; Colestipol; Dextrothyroxine; Fenofibrate; Humans; Hypercholesterolemia; Neomycin; Nicotinic Acids; Sitosterols	1980
The effect of etofibrate retard, bezafibrate and procetofen. Artery, 1980, Volume: 8, Issue:2 Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Lipoproteins; Male; Middle Aged; Patient Compliance; Propionates; Triglycerides	1980
[Comparative research on etofibrate retard and fenofibrate in hyperlipoproteinemia]. Die Medizinische Welt, 1980, Dec-12, Volume: 31, Issue:50 Topics: Aged; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Male; Middle Aged; Propionates; Triglycerides	1980
Delayed effects of ciprofibrate on rat liver peroxisomal properties and proto-oncogene expression. Biochemical pharmacology, 1995, Sep-28, Volume: 50, Issue:7 Topics: Acyl-CoA Oxidase; Animals; Clofibric Acid; Fenofibrate; Fibric Acids; Liver; Male; Microbodies; Microsomes, Liver; Mitochondria, Liver; Oxidoreductases; Proto-Oncogene Proteins; Rats; Rats, Wistar; Time Factors	1995
Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes. Fundamental and applied toxicology : official journal of the Society of Toxicology, 1995, Volume: 26, Issue:1 Topics: Animals; Cells, Cultured; Clofibric Acid; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Induction; Fenofibrate; Fibric Acids; Guinea Pigs; Humans; Liver; Male; Mass Spectrometry; Microbodies; Mixed Function Oxygenases; Palmitoyl Coenzyme A; Rats; Rats, Wistar; Species Specificity; Time Factors; Tumor Cells, Cultured	1995
Effect of peroxisomes proliferators and hypolipemic agents on mitochondrial inner membrane linked D-3-hydroxybutyrate dehydrogenase (BDH). Biochemistry and molecular biology international, 1995, Volume: 35, Issue:1 Topics: 2,4-Dichlorophenoxyacetic Acid; Animals; Binding, Competitive; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Hydroxybutyrate Dehydrogenase; Hypolipidemic Agents; In Vitro Techniques; Intracellular Membranes; Male; Microbodies; Mitochondria; Mitochondria, Liver; Phospholipids; Rats; Rats, Wistar; Tetrahymena pyriformis	1995
Hypercholesterolemia treatment in a renal transplant patient. Clinical nephrology, 1994, Volume: 41, Issue:5 Topics: Anticholesteremic Agents; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Male; Middle Aged; Postoperative Complications; Simvastatin	1994
Creatinine rise after fibrate therapy in renal graft recipients. Lancet (London, England), 1993, Mar-27, Volume: 341, Issue:8848 Topics: Bezafibrate; Clofibric Acid; Creatinine; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Kidney Transplantation; Male	1993
Studies on the in vitro reactivity of clofibryl and fenofibryl glucuronides. Evidence for protein binding via a Schiff's base mechanism. Biochemical pharmacology, 1993, Aug-03, Volume: 46, Issue:3 Topics: Buffers; Clofibric Acid; Fenofibrate; Glucuronates; Humans; In Vitro Techniques; Protein Binding; Serum Albumin; Solutions	1993
Effects of two peroxisome proliferators (ciprofibrate and fenofibrate) on peroxisomal membrane proteins and dihydroxyacetone-phosphate acyl-transferase activity in rat liver. Cellular and molecular biology (Noisy-le-Grand, France), 1993, Volume: 39, Issue:1 Topics: Acyltransferases; Animals; Clofibric Acid; Enzyme Induction; Fenofibrate; Fibric Acids; Glycerol-3-Phosphate O-Acyltransferase; Hydrogen-Ion Concentration; Hypolipidemic Agents; In Vitro Techniques; Liver; Male; Membrane Proteins; Microbodies; Rats; Rats, Wistar	1993
Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. The Biochemical journal, 1996, Mar-15, Volume: 314 ( Pt 3) Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Bezafibrate; Bile; Bile Canaliculi; Clofibrate; Clofibric Acid; DNA Primers; Drug Resistance, Multiple; Fenofibrate; Fibric Acids; Gemfibrozil; Gene Expression; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred Strains; Molecular Sequence Data; Multigene Family; Phospholipids; RNA, Messenger; RNA, Ribosomal, 18S	1996
Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate. Annals of clinical biochemistry, 1996, Volume: 33 ( Pt 2) Topics: Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Monitoring, Physiologic	1996
Effect of chloride channel blockers on the cardiac CFTR chloride and L-type calcium currents. Cardiovascular research, 1996, Volume: 32, Issue:2 Topics: Animals; Anthracenes; Calcium; Calcium Channel Blockers; Chloride Channels; Chlorides; Clofibric Acid; Colforsin; Cystic Fibrosis Transmembrane Conductance Regulator; Fenofibrate; Gemfibrozil; Glycolates; Guinea Pigs; Ion Transport; Mice; Myocardium; ortho-Aminobenzoates; Patch-Clamp Techniques; Stilbenes	1996
Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography. Journal of chromatography. B, Biomedical applications, 1996, Dec-13, Volume: 687, Issue:2 Topics: Bezafibrate; Calibration; Chromatography, High Pressure Liquid; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hypolipidemic Agents; Reproducibility of Results; Sensitivity and Specificity	1996
Fibrates and HDL cholesterol. Annals of clinical biochemistry, 1997, Volume: 34 ( Pt 1) Topics: Apolipoprotein A-I; Cholesterol, HDL; Clofibric Acid; Dose-Response Relationship, Drug; Female; Fenofibrate; Fibric Acids; Humans; Hypolipidemic Agents; Hypolipoproteinemias; Middle Aged; Probucol	1997
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1997, Volume: 21, Issue:2 Topics: Body Mass Index; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Prospective Studies; Sex Factors; Simvastatin; Weight Loss	1997
Peroxisome proliferation and beta-oxidation in Fao and MH1C1 rat hepatoma cells, HepG2 human hepatoblastoma cells and cultured human hepatocytes: effect of ciprofibrate. European journal of cell biology, 1997, Volume: 72, Issue:4 Topics: 3-Hydroxyacyl CoA Dehydrogenases; Animals; Cells, Cultured; Clofibric Acid; Enoyl-CoA Hydratase; Fenofibrate; Fibric Acids; Hepatoblastoma; Humans; Isomerases; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Microbodies; Microscopy, Electron; Multienzyme Complexes; Oxidoreductases; Peroxisomal Bifunctional Enzyme; Rats; Rats, Wistar; Tumor Cells, Cultured	1997
Activation of human liver 3alpha-hydroxysteroid dehydrogenase by clofibrate derivatives. The Journal of pharmacology and experimental therapeutics, 1998, Volume: 285, Issue:3 Topics: Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductases; Binding Sites; Clofibrate; Clofibric Acid; Dose-Response Relationship, Drug; Enzyme Activation; Fenofibrate; Humans; Hydrogen-Ion Concentration; Hydroxysteroid Dehydrogenases; Hypolipidemic Agents; Liver	1998
[Autoimmune hepatitis induced by fibrates]. Gastroenterologie clinique et biologique, 1998, Volume: 22, Issue:5 Topics: Aged; Autoimmune Diseases; Chemical and Drug Induced Liver Injury; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Humans; Hypolipidemic Agents; Male; Middle Aged	1998
Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha. Thrombosis and haemostasis, 1998, Volume: 80, Issue:6 Topics: 5,8,11,14-Eicosatetraynoic Acid; Alitretinoin; Animals; Apolipoprotein A-I; Cells, Cultured; Clofibrate; Clofibric Acid; Dimerization; Female; Fenofibrate; Fibric Acids; Fibrinogen; Gemfibrozil; Gene Expression Regulation; Genes, Reporter; Hypolipidemic Agents; Liver; Macaca fascicularis; Male; Peroxisome Proliferators; Plasminogen Activator Inhibitor 1; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Transcription Factors; Transcriptional Activation; Tretinoin	1998
Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood, 1999, May-01, Volume: 93, Issue:9 Topics: Animals; Cells, Cultured; Clofibrate; Clofibric Acid; DNA-Binding Proteins; Fenofibrate; Fibric Acids; Fibrinogen; Gene Expression Regulation; Hypolipidemic Agents; Kinetics; Liver; Male; Mice; Mice, Knockout; Peroxisome Proliferators; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors; Transcription, Genetic; Triglycerides	1999
The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicological sciences : an official journal of the Society of Toxicology, 1999, Volume: 48, Issue:1 Topics: Animals; Bezafibrate; Calcium; Clofibrate; Clofibric Acid; Diethylhexyl Phthalate; Energy Metabolism; Fenofibrate; Fibric Acids; Gemfibrozil; Intracellular Membranes; Male; Membrane Potentials; Mitochondria, Liver; Mitochondrial Swelling; Oxygen; Permeability; Peroxisome Proliferators; Pyrimidines; Rats; Rats, Sprague-Dawley; Trichloroethylene	1999
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. Arteriosclerosis, thrombosis, and vascular biology, 1999, Volume: 19, Issue:6 Topics: Bezafibrate; Cells, Cultured; Clofibric Acid; Endothelium, Vascular; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Plasminogen Activator Inhibitor 1; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic	1999
Implication of fibrate therapy for homocysteine. Lancet (London, England), 1999, Oct-02, Volume: 354, Issue:9185 Topics: Clofibric Acid; Fenofibrate; Fibric Acids; Glomerular Filtration Rate; Homocysteine; Humans; Hypolipidemic Agents; Kidney Transplantation; Renal Plasma Flow, Effective	1999
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2000, Volume: 15, Issue:12 Topics: Bezafibrate; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Kidney Diseases; Kidney Transplantation; Postoperative Period; Retrospective Studies; Urea	2000
Fibrate treatment can increase serum creatinine levels. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:6 Topics: Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Kidney Diseases; Urea	2001
Fibrate-induced increase in blood urea and creatinine. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:7 Topics: Bezafibrate; Blood Urea Nitrogen; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Diseases	2001
Effects of various fibrates on serum alkaline phosphatase activity. Atherosclerosis, 2002, Volume: 165, Issue:1 Topics: Alkaline Phosphatase; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Retrospective Studies; Treatment Outcome	2002
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells. Naunyn-Schmiedeberg's archives of pharmacology, 2003, Volume: 367, Issue:3 Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Embryonal; RNA, Messenger; Simvastatin; Time Factors; Transcription Factors; Tumor Cells, Cultured	2003
Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins. Acta cardiologica, 2003, Volume: 58, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Male; Microfilament Proteins; Middle Aged; Muscle Proteins; Pravastatin; Pyrroles; Retrospective Studies	2003
Fibrates and renal function. Clinical nephrology, 2003, Volume: 60, Issue:1 Topics: Adult; Aged; Clofibric Acid; Creatinine; Female; Fenofibrate; Fibric Acids; Glomerular Filtration Rate; Humans; Hypolipidemic Agents; Kidney; Male; Middle Aged	2003
Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis, 2004, Volume: 25, Issue:9 Topics: Acyl-CoA Oxidase; Animals; Apoptosis; Area Under Curve; Catalase; Cell Division; Clofibric Acid; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Endoplasmic Reticulum, Smooth; Fenofibrate; Fibric Acids; Gene Expression Profiling; Glutathione Peroxidase; Liver; Macaca fascicularis; Male; Mitochondria; Mitotic Index; Organ Size; Oxidative Stress; Peroxisomes; Proliferating Cell Nuclear Antigen; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thioredoxin-Disulfide Reductase; Transcription Factors	2004
PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells. Regulatory peptides, 2004, Aug-15, Volume: 120, Issue:1-3 Topics: Bezafibrate; Cell Proliferation; Clofibrate; Clofibric Acid; Colorectal Neoplasms; Fenofibrate; Fibric Acids; Gastrins; Gemfibrozil; Humans; Hypolipidemic Agents; Ligands; Peroxisome Proliferator-Activated Receptors; Protein Precursors; Pyrimidines; Radioimmunoassay; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Vasodilator Agents	2004
Hypolipidemic drugs affect monocyte IL-1beta gene expression and release in patients with IIa and IIb dyslipidemia. Journal of cardiovascular pharmacology, 2005, Volume: 45, Issue:2 Topics: Atorvastatin; Cells, Cultured; Clofibric Acid; Cytokines; Fenofibrate; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Interleukin-1; Lipids; Monocytes; Plasminogen Activator Inhibitor 1; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction	2005
Differential associations of statin and fibrate treatment with carotid arterial remodeling. American journal of hypertension, 2005, Volume: 18, Issue:11 Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography	2005
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. Journal of hepatology, 2006, Volume: 44, Issue:4 Topics: Animals; Apolipoprotein E2; Apolipoproteins E; ATP-Binding Cassette Transporters; Clofibric Acid; Dietary Fats; Disease Models, Animal; Disease Progression; Fatty Liver; Female; Fenofibrate; Gene Expression; Hyperlipidemias; Hypolipidemic Agents; Immunohistochemistry; Inflammation; Intercellular Signaling Peptides and Proteins; Liver; Macrophages; Mice; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Peroxisome Proliferator-Activated Receptors; Phospholipases A; Progranulins; Reverse Transcriptase Polymerase Chain Reaction; Stearoyl-CoA Desaturase; Vascular Cell Adhesion Molecule-1	2006
Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. Journal of lipid research, 2007, Volume: 48, Issue:8 Topics: Anticholesteremic Agents; Cells, Cultured; Cholesterol, HDL; Clofibric Acid; Dose-Response Relationship, Drug; Fenofibrate; Humans; Lipoproteins, HDL; Receptors, Lipoprotein; Scavenger Receptors, Class B; Thiourea	2007
Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. The Journal of biological chemistry, 2008, Apr-11, Volume: 283, Issue:15 Topics: Anticholesteremic Agents; Cell Line, Tumor; Clofibric Acid; DNA-Binding Proteins; Fenofibrate; Furin; Gene Expression Regulation, Enzymologic; Hepatocytes; Humans; Hydrocarbons, Fluorinated; Hyperlipoproteinemia Type II; Lipid Metabolism; Liver X Receptors; Orphan Nuclear Receptors; PPAR alpha; Pravastatin; Promoter Regions, Genetic; Proprotein Convertase 5; Proprotein Convertase 9; Proprotein Convertases; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Serine Endopeptidases; Sulfonamides; Up-Regulation	2008
Opposing roles of peroxisome proliferator-activated receptor alpha and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model. The Journal of biological chemistry, 2009, Jun-12, Volume: 284, Issue:24 Topics: Animals; Clofibric Acid; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Fasting; Female; Fenofibrate; Gene Expression Regulation, Enzymologic; Growth Hormone; Humans; Hypolipidemic Agents; Kidney; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microsomes, Liver; PPAR alpha; Pregnancy; RNA, Messenger; Sex Characteristics	2009
Probing the fibrate binding specificity of rat liver fatty acid binding protein. Journal of medicinal chemistry, 2009, Sep-10, Volume: 52, Issue:17 Topics: Animals; Binding Sites; Carboxylic Acids; Clofibric Acid; Esters; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Ligands; Liver; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Rats; Spectrometry, Fluorescence; Substrate Specificity; Temperature; Thermodynamics	2009
Differential induction of stearoyl-CoA desaturase 1 and 2 genes by fibrates in the liver of rats. Biological & pharmaceutical bulletin, 2012, Volume: 35, Issue:1 Topics: Animals; Bezafibrate; Clofibric Acid; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Activators; Fenofibrate; Gene Expression Regulation; Liver; Male; Rats; Rats, Wistar; RNA, Messenger; Stearoyl-CoA Desaturase	2012
Induction of 1-acylglycerophosphocholine acyltransferase genes by fibrates in the liver of rats. Biological & pharmaceutical bulletin, 2012, Volume: 35, Issue:9 Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Animals; Bezafibrate; Clofibric Acid; Fatty Acids; Fenofibrate; Fibric Acids; Gene Expression; Gene Expression Regulation; Liver; Male; Microsomes, Liver; Phosphatidylcholines; Rats; Rats, Wistar; RNA, Messenger; Stearoyl-CoA Desaturase	2012
Fibrates reduce triacylglycerol content by upregulating adipose triglyceride lipase in the liver of rats. Journal of pharmacological sciences, 2013, Volume: 123, Issue:4 Topics: Animals; Bezafibrate; Clofibric Acid; Fatty Liver; Fenofibrate; Lipase; Lipid Peroxidation; Liver; Male; Molecular Targeted Therapy; PPAR alpha; Rats; Rats, Wistar; Triglycerides; Up-Regulation	2013
A simple and sensitive method for the determination of fibric acids in the liver by liquid chromatography. Biological & pharmaceutical bulletin, 2014, Volume: 37, Issue:1 Topics: Acyl-CoA Oxidase; Animals; Bezafibrate; Chromatography, High Pressure Liquid; Clofibric Acid; Fenofibrate; Fibric Acids; Liver; Male; PPAR alpha; Rats; Rats, Wistar; Reproducibility of Results; RNA, Messenger	2014